About 11 results found for searched term "DUB-IN-2" (0.22 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M13626 | DUB-IN-2 | Deubiquitinase |
| DUB-IN-2 is a potent deubiquitinase inhibitor with an IC50 of 0.28 μM for USP8. | ||
| M2565 | PR-619 | Deubiquitinase |
| 2,6-Diamino-3,5-dithiocyanopyridine | ||
| PR-619 is a broad-spectrum reversible DUB (deubiquitinating enzyme) inhibitor of USP2, USP4, USP5, USP7 and USP8 with an EC50 of 3-9 μM. PR-619 also induces endoplasmic reticulum stress and endoplasmic reticulum stress-associated apoptosis. | ||
| M2890 | NSC 632839 | Others |
| F6 | ||
| NSC 632839 is not only a DUB inhibitor, but also a deSUMOylase inhibitor, it inhibits USP2, USP7, and SENP2 with IC50 of 45 μM, 37 μM, and 9.8 μM, respectively. | ||
| M3052 | TCID | Deubiquitinase |
| 4,5,6,7-Tetrachloroindan-1,3-dione | ||
| TCID is a DUB inhibitor for ubiquitin C-terminal hydrolase L3 with IC50 of 0.6 μM, 125-fold selective to L1. | ||
| M8473 | RA-9 | Others |
| RA-9 is a cell permeable and potent inhibitor of the ubiquitin-proteasome system (UPS) that targets deubiquitinating enzymes (DUB) without affecting 20S proteasome catalytic-core activity. | ||
| M8915 | Dubermatinib | TAM Receptor |
| TP-0903 | ||
| Dubermatinib (TP-0903) is a potent and selective AXL inhibitor with an IC50 value of 27 nM. | ||
| M9871 | GSK2643943A | Deubiquitinase |
| GSK2643943A is a deubiquitylating enzyme (DUB) inhibitor targeting USP20/Ub-Rho with an IC50 of 160 nM. GSK2643943A has anti-tumor efficacy and can be used for the research of oral squamous cell carcinoma (OSCC). | ||
| M13627 | DUB-IN-3 | Deubiquitinase |
| DUB-IN-3 is a potent deubiquitinase (USP) enzyme inhibitor extracted from reference compound 22c with an IC50 of 0.56 μM for USP8. | ||
| M13628 | EOAI3402143 | Deubiquitinase |
| EOAI3402143 is a deubiquitinase (DUB) inhibitor, which inhibits dose-dependently inhibits Usp9x/Usp24 and Usp5. | ||
| M25343 | Sudubrilimab | PD-1/PD-L1 |
| HS636 | ||
| Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment. | ||
| M54656 | NJH-2-056 | Others |
| NJH-2-056 is a deubiquitinase-targeting chimera (DUBTAC) linking EN523, a recruitment factor for OTUB1, to lumacaftor, a CFTR chaperone protein.NJH-2-056 can be used in cystic fibrosis-related studies. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
